NPI: 1164821559 · NATCHEZ, MS 39120 · General Acute Care Hospital · NPI assigned 08/21/2014
Authorized official LALOR, PAULA controls 20+ related entities in our dataset. Read more
| Authorized Official | LALOR, PAULA (DIRECTOR/DELEGATED OFFICIAL) |
| NPI Enumeration Date | 08/21/2014 |
Other providers sharing the same authorized official: LALOR, PAULA
| Year | Claims | Total Paid |
|---|---|---|
| 2018 | 80,427 | $3.18M |
| 2019 | 75,281 | $3.18M |
| 2020 | 58,572 | $2.19M |
| 2021 | 57,096 | $2.22M |
| 2022 | 72,235 | $2.42M |
| 2023 | 67,808 | $2.51M |
| 2024 | 48,582 | $1.81M |
| Code | Description | Claims | Beneficiaries | Total Paid |
|---|---|---|---|---|
| 99283 | Emergency department visit for the evaluation and management, moderate severity | 30,020 | 25,436 | $4.53M |
| 99284 | Emergency department visit for the evaluation and management, high severity | 14,353 | 11,945 | $2.63M |
| 99285 | Emergency department visit for the evaluation and management, high severity with immediate threat to life | 5,329 | 4,363 | $1.10M |
| 97110 | Therapeutic procedure, each 15 minutes; therapeutic exercises to develop strength and endurance, flexibility and range of motion | 21,144 | 4,190 | $752K |
| G0378 | Hospital observation service, per hour | 1,571 | 1,207 | $629K |
| 99282 | Emergency department visit for the evaluation and management, low to moderate severity | 7,521 | 6,429 | $617K |
| 96374 | Therapeutic, prophylactic, or diagnostic injection; intravenous push, single or initial substance | 6,832 | 5,601 | $522K |
| 92507 | Treatment of speech, language, voice, communication, and/or auditory processing disorder | 8,036 | 1,693 | $428K |
| 94640 | Pressurized or nonpressurized inhalation treatment for acute airway obstruction | 4,362 | 2,887 | $393K |
| 71045 | Radiologic examination, chest; single view | 10,706 | 8,861 | $362K |
| 96372 | Therapeutic, prophylactic, or diagnostic injection; subcutaneous or intramuscular | 9,791 | 7,841 | $360K |
| 96365 | Intravenous infusion, for therapy, prophylaxis, or diagnosis; initial, up to 1 hour | 4,517 | 3,468 | $337K |
| 99281 | Emergency department visit for the evaluation and management, self-limited or minor | 6,287 | 5,508 | $289K |
| 74176 | Computed tomography, abdomen and pelvis; without contrast material | 2,797 | 2,399 | $259K |
| 87426 | Infectious agent antigen detection, SARS-CoV-2 (COVID-19) | 8,812 | 7,753 | $258K |
| 70450 | Computed tomography, head or brain; without contrast material | 5,309 | 4,486 | $253K |
| 74177 | Computed tomography, abdomen and pelvis; with contrast material | 1,668 | 1,449 | $247K |
| 71046 | Radiologic examination, chest; 2 views | 5,648 | 4,805 | $228K |
| 93005 | Electrocardiogram, routine ECG with at least 12 leads; tracing only, without interpretation and report | 12,135 | 9,671 | $226K |
| 96361 | Intravenous infusion, hydration; each additional hour | 4,706 | 3,529 | $216K |
| 93306 | Echocardiography, transthoracic, real-time with image documentation, with and without Doppler, complete | 790 | 684 | $201K |
| 80053 | Comprehensive metabolic panel | 21,894 | 17,432 | $166K |
| 85025 | Blood count; complete (CBC), automated, and automated differential WBC count | 30,166 | 22,440 | $158K |
| 86900 | 2,816 | 2,097 | $144K | |
| 87400 | 10,243 | 9,045 | $142K | |
| 96375 | Therapeutic injection; each additional sequential IV push | 6,215 | 4,641 | $132K |
| 96360 | Intravenous infusion, hydration; initial, 31 minutes to 1 hour | 1,317 | 1,135 | $130K |
| 77067 | Screening mammography, bilateral, including computer-aided detection | 1,471 | 1,360 | $120K |
| C9803 | Hospital outpatient clinic visit specimen collection for severe acute respiratory syndrome coronavirus 2 (sars-cov-2) (coronavirus disease [covid-19]), any specimen source | 7,002 | 6,084 | $110K |
| 97530 | Therapeutic activities, direct patient contact, each 15 minutes | 2,908 | 676 | $97K |
| 36415 | Collection of venous blood by venipuncture | 31,956 | 23,265 | $82K |
| 87430 | 5,629 | 5,027 | $74K | |
| 96366 | Intravenous infusion, for therapy, prophylaxis, or diagnosis; each additional hour | 1,681 | 1,082 | $65K |
| 72100 | 1,291 | 1,092 | $63K | |
| 74018 | 1,422 | 1,242 | $60K | |
| D2930 | Prefabricated stainless steel crown - primary tooth | 968 | 317 | $60K |
| 83880 | 2,420 | 1,981 | $53K | |
| 84484 | 6,638 | 4,562 | $49K | |
| 86850 | 2,054 | 1,588 | $48K | |
| 81001 | 19,121 | 15,520 | $44K | |
| 86901 | 2,698 | 2,090 | $43K | |
| 73030 | 1,118 | 983 | $41K | |
| 73630 | 900 | 788 | $37K | |
| 81025 | 5,183 | 4,405 | $32K | |
| 80048 | Basic metabolic panel (calcium, ionized) | 5,809 | 4,244 | $31K |
| 80307 | Drug test(s), presumptive, any number of drug classes; immunoassay | 617 | 513 | $30K |
| 72125 | Computed tomography, cervical spine; without contrast material | 753 | 641 | $28K |
| 87807 | 2,338 | 2,086 | $26K | |
| 97162 | 843 | 695 | $26K | |
| 87040 | 3,731 | 1,920 | $25K | |
| 87086 | Culture, bacterial; quantitative colony count, urine | 4,230 | 3,566 | $24K |
| 80305 | 2,966 | 2,411 | $24K | |
| 82553 | 2,565 | 1,977 | $21K | |
| 87635 | Infectious agent detection by nucleic acid; SARS-CoV-2 (COVID-19), amplified probe | 629 | 567 | $21K |
| 73562 | 573 | 479 | $21K | |
| 97116 | 1,565 | 376 | $19K | |
| 85730 | 4,650 | 3,916 | $18K | |
| 82550 | 3,183 | 2,383 | $16K | |
| 83690 | 3,385 | 2,838 | $16K | |
| 73610 | 334 | 303 | $15K | |
| 36600 | 346 | 277 | $14K | |
| 84443 | Thyroid stimulating hormone (TSH) | 1,363 | 1,156 | $14K |
| 73560 | 413 | 359 | $14K | |
| 85610 | 5,301 | 4,421 | $13K | |
| 71275 | Computed tomographic angiography, chest, with contrast material | 157 | 131 | $13K |
| 82962 | 6,514 | 3,432 | $13K | |
| 87077 | 2,143 | 1,832 | $12K | |
| 71260 | Computed tomography, thorax, diagnostic; with contrast material | 153 | 133 | $12K |
| 83605 | 1,862 | 1,382 | $11K | |
| 85379 | 1,815 | 1,504 | $11K | |
| 83735 | 3,393 | 2,673 | $10K | |
| 73130 | 242 | 193 | $10K | |
| 59025 | Fetal non-stress test | 80 | 39 | $10K |
| 71250 | 359 | 319 | $10K | |
| D3220 | Therapeutic pulpotomy (excluding final restoration) - removal of pulp coronal to the dentinocemental junction | 245 | 58 | $9K |
| 82150 | 2,199 | 1,874 | $9K | |
| 84702 | 821 | 633 | $9K | |
| 41899 | Unlisted procedure, dentoalveolar structures | 78 | 75 | $8K |
| 76700 | Ultrasound, abdominal, real time with image documentation; complete | 151 | 132 | $8K |
| 72148 | Magnetic resonance imaging, lumbar spine; without contrast material | 120 | 107 | $8K |
| 87186 | 908 | 774 | $7K | |
| 99211 | Office or other outpatient visit for the evaluation and management of an established patient, minimal severity | 1,204 | 853 | $7K |
| 83036 | Hemoglobin; glycosylated (A1C) | 1,088 | 918 | $7K |
| 78815 | Positron emission tomography (PET) for limited area imaging | 14 | 13 | $7K |
| 80061 | Lipid panel | 594 | 534 | $6K |
| 93971 | 164 | 148 | $6K | |
| 82077 | 594 | 436 | $6K | |
| 73502 | 209 | 188 | $6K | |
| 76817 | Ultrasound, pregnant uterus, real time with image documentation, transvaginal | 83 | 60 | $6K |
| 97140 | Manual therapy techniques, each 15 minutes (e.g., mobilization/manipulation, manual lymphatic drainage) | 298 | 101 | $5K |
| 76805 | Ultrasound, pregnant uterus, real time with image documentation, fetal and maternal evaluation | 84 | 65 | $5K |
| 76856 | Ultrasound, pelvic (nonobstetric), real time with image documentation; complete | 72 | 67 | $5K |
| 76642 | 116 | 105 | $5K | |
| 90471 | Immunization administration (includes percutaneous, intradermal, subcutaneous, or intramuscular injections), 1 vaccine | 201 | 167 | $4K |
| 82803 | 356 | 251 | $4K | |
| U0003 | Infectious agent detection by nucleic acid (dna or rna); severe acute respiratory syndrome coronavirus 2 (sars-cov-2) (coronavirus disease [covid-19]), amplified probe technique, making use of high throughput technologies as described by cms-2020-01-r | 47 | 42 | $3K |
| 76705 | Ultrasound, abdominal, real time with image documentation; limited | 68 | 59 | $3K |
| 87491 | Infectious agent detection by nucleic acid; Chlamydia trachomatis, amplified probe | 91 | 80 | $3K |
| 87591 | Infectious agent detection by nucleic acid; Neisseria gonorrhoeae, amplified probe | 90 | 80 | $3K |
| 97161 | 55 | 50 | $3K | |
| G0463 | Hospital outpatient clinic visit for assessment and management of a patient | 746 | 528 | $3K |
| 36430 | 18 | 12 | $3K | |
| 76770 | 47 | 40 | $2K | |
| 70551 | Magnetic resonance imaging, brain; without contrast material | 42 | 37 | $2K |
| P9016 | Red blood cells, leukocytes reduced, each unit | 20 | 12 | $2K |
| 73590 | 48 | 47 | $2K | |
| M0243 | Intravenous infusion or subcutaneous injection, casirivimab and imdevimab includes infusion or injection, and post administration monitoring | 14 | 12 | $2K |
| 72040 | 45 | 40 | $2K | |
| 86920 | 16 | 12 | $2K | |
| 99214 | Office or other outpatient visit for the evaluation and management of an established patient, moderate complexity | 33 | 26 | $1K |
| 76536 | 35 | 26 | $1K | |
| 72131 | 29 | 27 | $1K | |
| J2550 | Injection, promethazine hcl, up to 50 mg | 2,441 | 1,832 | $1K |
| 93925 | 13 | 13 | $1K | |
| 84703 | 165 | 146 | $912.54 | |
| 70486 | 18 | 14 | $864.67 | |
| 72070 | 12 | 12 | $856.80 | |
| 80143 | 55 | 38 | $663.17 | |
| 80179 | 55 | 38 | $646.39 | |
| J7030 | Infusion, normal saline solution , 1000 cc | 2,137 | 1,639 | $596.58 |
| J0696 | Injection, ceftriaxone sodium, per 250 mg | 4,182 | 3,427 | $538.61 |
| 87070 | 68 | 61 | $528.33 | |
| J2274 | Injection, morphine sulfate, preservative-free for epidural or intrathecal use, 10 mg | 1,743 | 1,224 | $519.91 |
| D2391 | Resin-based composite - one surface, posterior, primary or permanent | 18 | 12 | $491.64 |
| 51702 | 30 | 27 | $473.87 | |
| 96376 | 2,265 | 1,279 | $455.83 | |
| 73110 | 17 | 13 | $390.03 | |
| 96367 | 13 | 12 | $353.89 | |
| 82607 | 27 | 24 | $293.81 | |
| Q9967 | Low osmolar contrast material, 300-399 mg/ml iodine concentration, per ml | 2,753 | 2,367 | $225.75 |
| 86140 | 77 | 58 | $196.17 | |
| J2405 | Injection, ondansetron hydrochloride, per 1 mg | 6,166 | 4,789 | $134.10 |
| 84550 | 38 | 30 | $130.67 | |
| 85651 | 41 | 39 | $123.54 | |
| U0002 | 2019-ncov coronavirus, sars-cov-2/2019-ncov (covid-19), any technique, multiple types or subtypes (includes all targets), non-cdc | 14 | 14 | $99.23 |
| J1100 | Injection, dexamethasone sodium phosphate, 1 mg | 3,115 | 2,684 | $77.23 |
| C9113 | Injection, pantoprazole sodium, per vial | 369 | 271 | $63.56 |
| J1885 | Injection, ketorolac tromethamine, per 15 mg | 5,427 | 4,573 | $52.95 |
| 81003 | 23 | 21 | $24.42 | |
| J2175 | Injection, meperidine hydrochloride, per 100 mg | 1,099 | 895 | $19.18 |
| J1170 | Injection, hydromorphone, up to 4 mg | 1,777 | 1,149 | $16.87 |
| J3010 | Injection, fentanyl citrate, 0.1 mg | 3,207 | 2,623 | $16.80 |
| J2270 | Injection, morphine sulfate, up to 10 mg | 231 | 157 | $2.46 |
| J2250 | Injection, midazolam hydrochloride, per 1 mg | 1,679 | 1,361 | $0.64 |
| J2704 | Injection, propofol, 10 mg | 2,826 | 2,270 | $0.00 |
| Q0162 | Ondansetron 1 mg, oral, fda approved prescription anti-emetic, for use as a complete therapeutic substitute for an iv anti-emetic at the time of chemotherapy treatment, not to exceed a 48 hour dosage regimen | 1,114 | 975 | $0.00 |
| J0690 | Injection, cefazolin sodium, 500 mg | 1,268 | 995 | $0.00 |
| J0360 | Injection, hydralazine hcl, up to 20 mg | 110 | 94 | $0.00 |
| Q9963 | High osmolar contrast material, 350-399 mg/ml iodine concentration, per ml | 188 | 161 | $0.00 |
| J2060 | Injection, lorazepam, 2 mg | 95 | 79 | $0.00 |
| J2360 | Injection, orphenadrine citrate, up to 60 mg | 462 | 418 | $0.00 |
| J0330 | Injection, succinylcholine chloride, up to 20 mg | 91 | 76 | $0.00 |
| J7512 | Prednisone, immediate release or delayed release, oral, 1 mg | 54 | 51 | $0.00 |
| 96368 | 12 | 12 | $0.00 | |
| J2543 | Injection, piperacillin sodium/tazobactam sodium, 1 gram/0.125 grams (1.125 grams) | 22 | 12 | $0.00 |
| J1030 | Injection, methylprednisolone acetate, 40 mg | 44 | 41 | $0.00 |
| J1940 | Injection, furosemide, up to 20 mg | 93 | 64 | $0.00 |
| J7040 | Infusion, normal saline solution, sterile (500 ml = 1 unit) | 24 | 14 | $0.00 |
| J0290 | Injection, ampicillin sodium, 500 mg | 536 | 429 | $0.00 |
| J2919 | Injection, methylprednisolone sodium succinate, 5 mg | 52 | 36 | $0.00 |
| G8979 | Mobility: walking & moving around functional limitation, projected goal status, at therapy episode outset, at reporting intervals, and at discharge or to end reporting | 29 | 25 | $0.00 |
| J1171 | Injection, hydromorphone, 0.1 mg | 39 | 31 | $0.00 |
| J2930 | Injection, methylprednisolone sodium succinate, up to 125 mg | 505 | 410 | $0.00 |
| 90714 | 70 | 51 | $0.00 | |
| A9552 | Fluorodeoxyglucose f-18 fdg, diagnostic, per study dose, up to 45 millicuries | 14 | 13 | $0.00 |
| J1200 | Injection, diphenhydramine hcl, up to 50 mg | 163 | 137 | $0.00 |
| 99218 | 42 | 24 | $0.00 | |
| J0780 | Injection, prochlorperazine, up to 10 mg | 17 | 13 | $0.00 |
| J3475 | Injection, magnesium sulfate, per 500 mg | 30 | 24 | $0.00 |
| 90715 | 12 | 12 | $0.00 | |
| J2272 | Injection, morphine sulfate (fresenius kabi), not therapeutically equivalent to j2270, up to 10 mg | 14 | 14 | $0.00 |